Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.43% | 0.80% | 26.21% | -258.24% | 8.10% |
| Total Depreciation and Amortization | 18.67% | 50.76% | 48.92% | 42.44% | 52.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -56.05% | 121.66% | -121.49% | 84.60% | 70.35% |
| Cash from Operations | -22.25% | 52.54% | 46.35% | 72.18% | 46.79% |
| Capital Expenditure | 32.00% | 100.97% | 98.45% | 83.58% | 88.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.39% | -954.17% | 21.55% | -176.75% | 66.24% |
| Cash from Investing | 50.71% | 48.67% | 82.36% | 9.30% | 68.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 29.73% | -104.20% | -- |
| Issuance of Common Stock | -- | -55.23% | -100.00% | -- | -95.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -55.23% | -96.14% | 12,723.08% | -93.42% |
| Foreign Exchange rate Adjustments | -230.39% | 219.41% | -129.56% | 143.15% | 97.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.51% | 92.73% | -242.92% | 136.80% | -236.78% |